Smart + Strong.
All Rights Reserved.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.
Massachusetts General Hospital recently became the first hospital in the United States to use it.
United HealthCare opened up access in order to settle a $300 million class action lawsuit brought against it by HCV-positive policyholders.
Despite the expansion of HIV treatment, rates of end-stage liver disease among those coinfected with hepatitis B or C remain unchanged.
The Albert and Mary Lasker Foundation’s annual awards honor several researchers whose work contributed to the development of HCV treatment.
Immunizations are safe and effective, so why doesn’t everyone protect their children?
Chronic fatigue among those with hep C may be partly a result of liver inflammation and scarring related to the infection.
While one in four people with hep C have advanced liver damage, many living with the virus aren’t even in regular medical care.
Editor-in-Chief of Hepatology, Medicine & Policy reflects on the need to bring health systems questions into the viral hepatitis discourse
This woman did not let denial of hepatitis C treatment stop her from getting the medications she needed.
In 2012, the AHSA hired a medical technician at the facility who had a long disciplinary record of drug use on the job.
Tennessee is one of the best places in the United States to get a liver transplant. But new rules could change that by mid-October.
Risk of hepatitis C when there is a potential for blood-to-blood contact.
Interim results of a mid-level trial suggest that six or eight weeks of odalasvir, AL-335 and Olysio (simeprevir) work well against hep C.
However, advocates say the state’s updated coverage policies still don’t go far enough.
The PROP UP study is evaluating patient-reported outcomes associated with the treatment of hepatitis C infection and benefits of viral cure.